DURHAM, N.C. – The U.S. Food and Drug Administration has approved Priovant Therapeutics’ Lisraya for adults with dermatomyositis, giving the Durham biotechnology company approval for the first oral treatment option for the rare autoimmune disease.

Lisraya, the brand name for brepocitinib, is a once-daily 30-milligram tablet. Priovant said it can be prescribed in the United States immediately.

Dermatomyositis is an autoimmune disease in which the immune system attacks muscles and skin, causing inflammation, progressive muscle weakness and distinctive rashes. The FDA said patients have long had limited treatment options.

The agency based the approval on a randomized, double-blind, placebo-controlled phase 3 study involving 241 adults over 52 weeks. Patients receiving the approved 30-milligram dose had a higher average Total Improvement Score than those receiving a placebo, along with improvements in physical function and skin disease activity. The FDA also said patients were more likely to reduce corticosteroid use.

The most common adverse reactions included upper respiratory tract infection, headache, fatigue, urinary tract infection and nausea. Lisraya carries a boxed warning for serious infections, increased all-cause mortality, malignancies, major adverse cardiovascular events and thrombosis.

The FDA granted Lisraya Priority Review and Orphan Drug designations. The approval was granted to Priovant Therapeutics, a Roivant Sciences company.

For Priovant, the approval moves Lisraya from clinical development into commercial availability and gives the Durham life-sciences sector a new FDA-approved product tied to a locally based biotechnology company.